Pharmaceutically active disubstituted triazine derivatives

Compounds having the general formula (I)

• wherein
• R1 is
• L is a bond or —CR5R6—, —CR5R6—CR7R8—, —CR5R6—CR7R8—CR9R10—, —CR5R6—CR7R8—CR9R10—CR11R12—;
• R5-R12 represent independently of each other —H, —CH3, —C2H5, —C3H7, —F, —Cl, —Br, —I;
• R3 is selected from —H, —NO2, —CN, —Br, —I, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2CH(CH3)2, —CH(CH3)C2H5, —CR13R14R21, —CR13R14—CR15R16R21, CR13R14—CR15R16—CR17R18R21, —CR13R14—CR15R16—CR17R18—CR19R20R21, —SO2R22, —CONR23R24, —NR25SO2NR23R24, —NR25SO2R22, —NR25CONR23R24, —SO2NR23R24, —SO(NR26)R22;
• R13-R21 and R29-R32 represent independently of each other —H, —CH3, —C2H5, —C3H7, —C4H9, —F, —Cl, —Br, —I;
• R22 and R28 are independently selected from R27′, —CR13R14R21, —CR13R14—CR15R16R21, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30R21, —CR13R14—CR15R16—CR17R18R21, —CR13R14—CR15R16—CR17R18—CR19R20R21, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30—CR31R32R21, —CH2Ph;
• —CH2Ph the phenyl group of which may further be substituted by one, two, three, four or five substituents selected from the group consisting of —CH3, —C2H5, —C3H7, —F, —Cl, —Br and —I;
• R23 and R24 are independently selected from —H, —CR13R14R21, —CR13R14—CR15R16R21, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30R21, —CR13R14—CR15R16—CR17R18R21, —CR13R14—CR15R16—CR17R18—CR19R20R21, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30—CR31R32R21, —CR13R14—CR15R16—O—R33, —CR13R14—CR15R16—CR17R18—O—R33, —CR13R14—CR15R16—NR33R34, —CR13R14—CR15R16—CR17R18—NR33R34, —CR13R14—CR15R16—CR17R18—CR19R20—NR33R34, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30—NR33R34, -Ph, —CH2PH, phenyl group which may further be substituted by one, two, three, four or five substituents selected from the group consisting of —CH3, —C2H5, —C3H7, —F, —Cl, —Br and —I;
• —CH2Ph the phenyl group of which may further be substituted by one, two, three, four or five substituents selected from the group consisting of —CH3, —C2H5, —C3H7, —F, —Cl, —Br and —I;
• or
• both residues R23 and R24 together form with the nitrogen atom to which they are attached an azetidine, pyrrolidine, piperidine, piperazine, azepane, or morpholine ring;
• R25 is selected from —H, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5 or —C(CH3)3;
• R26 is —H, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CR13R14R21, —COR28, —CR13R14—CR15R16R21, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30R21, —CR13R14—CR15R16—CR17R18R21, —CR13R14—CR15R16—CR17R18—CR19R20R21, —CR13R14—CR15R16—CR17R18—CR19R20—CR29R30—CR31R32R21, —COOR28, —R27;
• R27, R27′ and R27″ are independently selected from
• these C3-C10-cycloalkyl groups may further be substituted by one, two, three, four, five or more substituents selected from the group consisting of —F, —Cl, —Br and —I;
• R33 and R34 represent independently of each other —H, —CH3, —C2H5, —C3H7, —C4H9, —CH2Ph, —COOC(CH3)3, —COOCH3, —COOCH2CH3, —COOCH2CH2CH3, —COOCH(CH3)2, —COOCH2Ph, —COCH3;
• R4 is selected from —H, —NO2, —CN, —F, —Cl, —Br, —I, —CR35R36R37, —CR35R36—CR38R39—CR40R41—CR42R43R37, —O—CR35R36—CR38R39R37, —O—CR35R36—CR38R39—CR40R41R37, —CR35R36—CR38R39—CR40R41R37, —O—CR35R36—CR38R39—CR40R41—CR42R43R37, —CR35R36—CR38R39R37, —O—CR35R36CR38R39—CR40R41—CR42R43—CR44R45R37, —O—CR35R36R37, —O—CR35R36—CR38R39—CR40R41—CR42R43—CR44R45—CR46R47R37, —CR35R36—CR38R39—CR40R41—CR42R43—CR44R45R37, —OCH2Ph, —R27″, —O—R27″, —CR35R36—CR38R39—CR40R41—CR42R43—CR44R45—CR46R47R37,
• R35-R47 represent independently of each other —H, —CR48R49R50, —OR48R49—CR51R52R50, —CR48R49—CR51R52—CR53R54R50, —CR48R49—CR51R52—CR53R54—CR55R56R50, —F, —Cl, —Br, —I;
• R48-R56 represent independently of each other —H, —F, —Cl, —Br, —I;
• R4 together with R22 or R23 or R24 or R25 may form a group —CH2CH2— or —CH2CH2CH2— if R4 is attached ortho to -L—R3;
• R2 is selected from
• B is a bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, —CF2—, —CH2O—, —CH2OCH2—, —CH2CH2O—, —CH2NH—, —CH2N(CH3)—, —CH2NHCH2—, —CH2N(CH3)CH2—, —CH2CH2NH—, —CH2CH2N(CH3)—;
• R57 is —H, —CH3, —CF3, —CHF2, —CH2F, —COOCH3, —COOCH2CH3, —COOH, —COOCH2Ph, —COOCH2CH2CH3, —COOCH(CH3)2, —COOCH2CH2CH2CH3, —COOCH(CH3)(CH2CH3), —COOCH2CH(CH3)2, —COOC(CH3)3, —CONH2, -Ph, —CONH(CH3), —CON(CH3)2, —CN, —NH2, —NH(CH3), —N(CH3)2, —NH(CH2CH3), —N(CH3)(CH2CH3), —N(CH2CH3)2, pyrrolidin-1-yl, piperidin-1-yl, azetidin-1-yl, morpholin-4-yl;
• R58 is —H, —CH3, —F, —Cl, —CF3, —CH2OCH3;
• R59 is —H, —CH3, —F, —Cl, —CF3, -Ph, —CH2OCH3;
• and
• R60 is —H, —CH3, —CF3, —COCH3, —COOCH3, —COOCH2CH3, —COOC(CH3)3, —COOCH2Ph;
• Y is —O—, —S—, —NH—, or —N(CH3)—;
• R61 is —H, —CH3, —CF3, —CH2CH3, —CH2CH2CH3, —COOCH3, —COCH2CH3, —COOH, —CONH2, —CN, —CH2OCH3, —CH2OH, phenyl, —CH2Ph, —CH2OPh, —CH2CH2Ph;
• R62 and R63 are independently selected from —H, —CH3, —CF3, —CH2CH3, —CN, —F, —Cl, —Br, —OH, —NH2, —OCH3, —SCH3, —SO2CH3;
• R64 and R65 are independently selected from —H, —CH3, —CF3, —CH2CH3, —CN, —F, —Cl, —Br, —OH, —NH2, —OCH3;
• R66 and R67 are independently selected from —H, —CH3, —CF3, —CH2CH3, —CN, —F, —Cl, —Br;
• R68 is selected from —H, —CH3, —CF3, —CH2CH3, —CN, —F, —Cl, —Br, —COOH, —COOCH3, —COOCH2CH3, —CONH2, —OH, —OCH3, —NH2;
• R69 is selected from —H, —CH3, —CH2CH3;
• R70 and R71 are independently selected from —H, —CH3, —CF3, —CH2CH3, —CN, —F, —Cl, —Br, —COOH, —COOCH3, —COOCH2CH3, —CONH2, —NH2;
• and
• R72 is selected from —H, —CH3, —CF3, —CH2CH3;
• and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, prodrugs, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.